Canning Peter, Birchall Kristian, Kettleborough Catherine A, Merritt Andy, Coombs Peter J
Centre for Therapeutics Discovery, LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK.
Centre for Therapeutics Discovery, LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK.
Drug Discov Today. 2020 Sep 10. doi: 10.1016/j.drudis.2020.09.003.
Here, we describe a novel workflow combining informatic and experimental approaches to enable evidence-based prioritising of targets from large sets in parallel. High-throughput protein production and biophysical fragment screening is used to identify those targets that are tractable and ligandable. As proof of concept we have applied this to a set of antibacterial targets comprising 146 essential genes. Of these targets, 51 were selected and 38 delivered results that allowed us to rank them by ligandability. The data obtained against these derisked targets have enabled rapid progression into structurally enabled drug discovery projects, demonstrating the practical value of the fragment-based target screening workflow.
在此,我们描述了一种新颖的工作流程,该流程结合了信息学和实验方法,能够基于证据并行地从大量数据集中对靶点进行优先级排序。高通量蛋白质生产和生物物理片段筛选用于识别那些易于处理且可结合配体的靶点。作为概念验证,我们已将此方法应用于一组包含146个必需基因的抗菌靶点。在这些靶点中,选择了51个,其中38个产生了结果,使我们能够根据配体结合能力对它们进行排名。针对这些经过风险评估的靶点所获得的数据已推动其快速进入基于结构的药物发现项目,证明了基于片段的靶点筛选工作流程的实际价值。